TARS logo

TARSUS PHARMACEUTICALS INC

TARSNASDAQ
πŸ† #1445 by market capEarnings Feb 22US Equity
$73.01β–Ό $4.66 (βˆ’6.00%)
Market closed Β· at close
πŸ””
Track TARS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$3.60B
Small Cap
πŸ“ˆRevenue Growth (YoY)
146.7%
High Growth
πŸ“ŠGross Margin
93.2%
High
πŸ’΅FCF Margin
5.6%
Moderate
βš–οΈP/S Ratio
5.3x
Fair
Otter Score
80
Strong
No chart data available for TARS.

Trading Snapshot

Day Range
$72.74 – $78.11
52-Week Range
$53.89 – $91.53
Volume (shares)
706,771
Avg Volume (shares)
β€”
Shares Outstanding
49.3M
Next Earnings
2027-02-22

Fundamentals Snapshot

Annual Revenue
$451M
Last Q Revenue
$195M
P/E Ratio
-4.8
P/S Ratio
5.3x
EPS (TTM)
$-15.13
Dividend Yield
0.00%
Dilution (1yr)
+11.0%
TARS logo

TARSUS PHARMACEUTICALS INC

TARS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$451Mβ–² +146.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.2%β–² +0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$71Mβ–Ό βˆ’41.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$22Mβ–Ό βˆ’73.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
42.8Mβ–² +11.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$90Mβ–² +$68M YoY
StockOtter Β· stockotter.space

About TARSUS PHARMACEUTICALS INC

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.